Teaching hospital Program year 2025 Source: CMS Open Payments

City of Hope National Medical Ctr

CCN 050146 CMS hospital 15709

Open in the dashboard

General payments

$580,823,496

1,179 payments

Research payments

$327,402,706

16,033 payments

Through program year 2025, City of Hope National Medical Ctr is reported as receiving $580,823,496 in general payments and $327,402,706 in research payments from drug and medical device manufacturers.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows

General

’19 ’20 ’21 ’22 ’23 ’24 ’25

Peak $378.6M

Research

’19 ’20 ’21 ’22 ’23 ’24 ’25

Peak $67.3M

Year	Kind	Amount	Payments
2025	General	$2,001,158	134
2025	Research	$67,291,839	3,954
2024	General	$1,235,319	126
2024	Research	$50,112,141	2,822
2023	General	$950,245	144
2023	Research	$47,719,911	2,482
2022	General	$6,193,600	129
2022	Research	$49,426,488	1,402
2021	General	$41,921,430	137
2021	Research	$42,210,939	1,610
2020	General	$149,882,018	189
2020	Research	$36,520,069	2,188
2019	General	$378,639,726	320
2019	Research	$34,121,318	1,575

Breakdown

Who paid General payments · program years 2019–2025

Genentech, Inc. $574,595,528 507 payments
AstraZeneca Pharmaceuticals LP $885,602 40 payments
National Marrow Donor Program $817,520 16 payments
Agilent Technologies, Inc. $669,923 15 payments
Pfizer Inc. $555,750 19 payments
Sanofi US Services Inc. $413,889 17 payments
Kyowa Kirin, Inc. $159,416 31 payments
Takeda Pharmaceuticals U.S.A., Inc. $136,000 13 payments
BeOne Medicines USA, Inc. $119,375 4 payments
Amgen Inc. $104,044 15 payments
Other $2,366,449 502 payments

What the payments were for General payments · program years 2019–2025

Royalty or License $573,981,884 497 payments
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,273,786 102 payments
Space rental or facility fees (teaching hospital only) $1,753,301 277 payments
Consulting Fee $1,178,159 73 payments
Grant $980,212 46 payments
Long term medical supply or device loan $444,339 26 payments
Education $90,567 12 payments
Debt forgiveness $49,789 82 payments
Charitable Contribution $40,033 23 payments
Gift $30,934 37 payments
Other $494 4 payments

Products named General payments · program years 2019–2025

Ocrevus $78,879,124 32 payments
Rituxan $65,079,481 48 payments
Perjeta $54,462,555 23 payments
Herceptin $49,832,191 25 payments
Avastin $42,299,722 26 payments
Actemra $20,595,168 27 payments
Xolair $20,429,047 23 payments
Lucentis $8,701,805 10 payments
Tecentriq $4,233,854 4 payments
Hemlibra $4,084,193 5 payments
Other $13,618,711 558 payments

A payment can name more than one product, so these amounts overlap.

Records

1,179 general · 16,033 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

A teaching hospital's total is institutional. It is money reported as going to the hospital itself, and it is kept separate from anything reported about the individual clinicians who work there — the two are never added together.